| Serial Number | 79345166 |
| Word Mark | BIVICTRIX |
| Filing Date | Tuesday, February 22, 2022 |
| Status | 645 - FINAL REFUSAL - MAILED |
| Status Date | Monday, September 30, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceutical preparations, namely, preparations for the treatment of cancer; medical preparations, namely, preparations for the treatment of cancer; veterinary preparations, namely, preparations for the treatment of cancer; dietetic food and substances adapted for medical or veterinary use; dietary supplements for human beings and animals; antibodies for medical purposes; anti-cancer drugs; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-infective antibiotics; anti-infective preparations; anti-infectives; anti-inflammatories; antiparasitic preparations; anti-viral agents; biological adjuvants for medical purposes; biological preparations for medical purposes, namely, for the treatment of cancer; biological preparations for the treatment of cancer; biological preparations for veterinary purposes; biological diagnostic reagents for medical use; biological diagnostic reagents for veterinary use; biological tissue cultures for medical purposes; biopharmaceutical preparations for the treatment of cancer; biotechnological preparations for medical use for the treatment of cancer; blood components in the nature of blood protein fractions, blood cellular fractions, blood plasma and cord blood for medical purposes; cardiovascular pharmaceuticals; cardiovascular preparations; cells for medical use; cellular function activating agents for medical purposes; chemical adjuvants for medical purposes; chemical preparations for medical purposes, namely, for prevention or treatment of cancer; chemical preparations for pesticidal purposes, namely, pesticides; chemical preparations for pharmaceutical purposes, namely, for prevention or treatment of cancer; chemical preparations for testing blood for medical purposes; chemical reagents for medical use; chemical preparations for pharmaceutical use, namely, for prevention or treatment of cancer; chemotherapeutics; clinical diagnostic reagents for medical use; clinical medical reagents; pharmaceutical compounds for treating cancer; pharmaceutical compounds for treating correlated pulmonary syndromes; pharmaceutical compounds for treating respiratory diseases; cord blood; cord blood for medical purposes; culture media for use in treatment of cancer for medical use; cultures of microorganisms and mammalian cultures for medical use; cytostatic drugs for medical purposes; cytostatics for medical purposes; cytostatics for pharmaceutical purposes; diagnostic agents for medical use; diagnostic agents for pharmaceutical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; diagnostic preparations for medical use; diagnostic preparations and materials in the nature of cancer diagnostics for medical purposes; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic reagents for medical use; diagnostic reagents for medicinal use; diagnostic substances for medical use; diagnostic testing materials in the nature of cancer diagnostics for medical use; drugs for medical purposes for the treatment of cancer; haemostatic preparations in the nature of medical haemostatic paste, haemostatic pencils; homeopathic medicines in the nature of pharmaceuticals for use in the treatment of cancer; immunomodulators; immunostimulants; immunosuppressants for use following transplantation in the case of graft rejection; immunotherapeutic agents for bacterial infections; in vitro diagnostic preparations for medical use; living cells for medical use; living cells for veterinary use; medicines, namely, medicines for cancer disorders; medicines for human purposes, namely, cancer medicines; medicines for intestinal disorders; medicines for the treatment of gastrointestinal diseases; medicines for treating intestinal disorders; pain relief preparations in the nature of pain relief medication; pharmaceutical compositions, namely, preparations for the treatment of cancer; pharmaceutical drugs, namely, preparations for the treatment of cancer; pharmaceutical preparations, namely, preparations for the treatment of cancer; pharmaceutical preparations and substances, namely, preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for use in gynecology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in the field of anesthesia; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations and substances with antipyretic properties; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for human use, namely, preparations for the treatment of cancer; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for medical purposes, namely, preparations for the treatment of cancer; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of allergies; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the prevention of diseases of the genitourinary system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for the prevention of diseases of the metabolic system; pharmaceutical preparations for the prevention of diseases of the musculo-skeletal system; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the prevention of disorders caused by bacteria; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the prevention of disorders of the endocrine system; pharmaceutical preparations for the prevention of disorders of the genitourinary system; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for the prevention of disorders of the musculo-skeletal system; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of disorders of the respiratory system; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the prevention of ocular diseases; pharmaceutical preparations for the prevention of ocular disorders; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of diseases caused by bacteria; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the genitourinary system; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of diseases of the musculo-skeletal system; pharmaceutical preparations for the treatment of disorders caused by bacteria; pharmaceutical preparations for the treatment of disorders of the endocrine system; pharmaceutical preparations for the treatment of disorders of the genitourinary system; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of esophagitis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of Musculo-skeletal disorders; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating digestive system disorders; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for treating rheumatological diseases; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for treating skeletal diseases; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for treating the symptoms of radiation sickness; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for use in urology; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; preparations for the treatment of asthma; radioactive substances for medical purposes; radio-isotope markers for therapeutic or diagnostic use; radiological contrast substances for medical purposes; radiopharmaceutical products, namely, pharmaceutical products for the prevention or treatment of cancer; clinical medical reagents for analytical purposes; clinical reagents for medical use; clinical medical reagents for use in diagnostic tests; reconstituted cells for clinical treatments for skin care; reconstituted cells for medical treatments for skin care; tissue-regenerative pharmaceutical preparations; tissues for medical use in the nature of biological tissue grafts and human allograft tissue |
| Goods and Services | Medical services; health care; providing information and advice in relation to medicines and health in the field of cancer diagnosis and treatment; provision of information relating to cancer treating medicine; providing news and information in the field of cancer treating medicine; information and advice in relation to the aforesaid |
| Goods and Services | Medical, apparatus and instruments, namely, apparatus and instruments for use in cancer treatment; medical devices, namely, medical devices for use in cancer treatment; medical instruments for application in human bodies for use in cancer treatment; medical testing instruments for use in cancer diagnosis and treatment; medical diagnostic apparatus for medical purposes for use in cancer diagnosis; applicators for pharmaceutical preparations in the nature of drug delivery devices; drug delivery devices sold empty, namely, syringes, infusion sets |
| Goods and Services | Scientific and technological services and research and design relating thereto, namely, in the field of cancer diagnosis and treatment; industrial analysis in the field of cancer diagnosis and treatment; Industrial research in the field of cancer diagnosis and treatment; pharmaceutical and therapeutics product development; pharmaceuticals and therapeutics research services; laboratory research services relating to pharmaceuticals and therapeutics; information and advice in relation to the aforesaid |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 15, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 15, 2022 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 15, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 15, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | BIVICTRIX LIMITED |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, July 14, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, July 15, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, July 19, 2022 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, December 6, 2022 | ASSIGNED TO EXAMINER |
| Monday, December 19, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, December 20, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, February 15, 2023 | REFUSAL PROCESSED BY MPU |
| Wednesday, February 15, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, March 6, 2023 | REFUSAL PROCESSED BY IB |
| Tuesday, August 15, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, August 15, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, August 21, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, December 20, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Monday, October 2, 2023 | SUSPENSION LETTER WRITTEN |
| Monday, October 2, 2023 | LETTER OF SUSPENSION E-MAILED |
| Monday, October 2, 2023 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Wednesday, December 20, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Tuesday, April 2, 2024 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Monday, September 30, 2024 | FINAL REFUSAL WRITTEN |
| Monday, September 30, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, September 30, 2024 | FINAL REFUSAL E-MAILED |
| Sunday, January 7, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |